EUVIMEDEUVIMED entdecken
Crossref

Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five‐year clinical outcomes

Bade Gulec iD, Elif Everest, Ogeday Derin Gorkey, Metehan Koc, Melih Tutuncu, Sabahattin Saip, Aksel Siva, Ugur Uygunoglu

European Journal of Neurology · 2023

DOI: 10.1111/ene.15913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Bade Gulec und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with multiple sclerosis (MS) who discontinue fingolimod might present with rebound activity. The reasons for the development of rebound have been identified, but there are limited data on the long‐term clinical outcomes of these patients. This study aimed to compare the long‐term outcomes of patients with MS with and without rebound activity after fingolimod discontinuation.

Methods

A total of 31 patients who discontinued fingolimod for various reasons with a minimum follow‐up of 5 years were included in the study. Of these, 10 were assigned to the rebound group and 21 to the non‐rebound group. Clinical and demographic data and 5‐year clinical outcomes of both groups were prospectively examined.

Results

At fingolimod initiation, there were no significant differences in age, disease duration, and Expanded Disability Status Scale (EDSS) score. The annualized relapse rate (ARR) was significantly higher in the rebound group than in the non‐rebound group before the fingolimod treatment ( p = 0.005). In the rebound group, EDSS scores 2 months after rebound treatment and at the 5‐year follow‐up were not significantly different than before fingolimod initiation ( p = 0.14 and p = 0.46, respectively). The last recorded EDSS was significantly higher in the non‐rebound group than in the rebound group (3.6 ± 2.3 vs. 2.15 ± 1.4, p = 0.045). At the last follow‐up, one patient was diagnosed with secondary progressive multiple sclerosis in the rebound group (10%), and 11 patients were in the non‐rebound group (52.4%, p = 0.05).

Conclusion

When rebound activity is well‐monitored and treated after fingolimod discontinuation, no overall EDSS change is expected in the long‐term follow‐up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic ProgressiveHumansFingolimod HydrochlorideRecurrenceImmunosuppressive Agents

Stichwörter der Autor:innen

annualized relapse rateclinical outcomefingolimod cessationfingolimod reboundmultiple sclerosis

Substanzen

Fingolimod HydrochlorideImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Neurology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

ORCID-Profile: Bade Gulec

Zitieren

APA

Gulec, B., Everest, E., Gorkey, O. D., Koc, M., Tutuncu, M., Saip, S., Siva, A., & Uygunoglu, U. (2023). Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five‐year clinical outcomes. European Journal of Neurology. https://doi.org/10.1111/ene.15913

Vancouver

Gulec B, Everest E, Gorkey OD, Koc M, Tutuncu M, Saip S, et al. Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five‐year clinical outcomes. European Journal of Neurology. 2023. doi:10.1111/ene.15913

BibTeX
@article{Gulec2023,
  author = {Gulec, Bade and Everest, Elif and Gorkey, Ogeday Derin and Koc, Metehan and Tutuncu, Melih and Saip, Sabahattin and Siva, Aksel and Uygunoglu, Ugur},
  title = {Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five‐year clinical outcomes},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15913}
}
Kostenlos starten →